Alumis Inc. (NASDAQ: ALMS) is a biopharmaceutical company focused on developing advanced therapies for immune-mediated diseases. The company is currently in the late stages of its clinical program, specifically targeting moderate-to-severe plaque psoriasis with its drug, envudeucitinib. Alumis is competing in a market with other pharmaceutical companies that are also developing treatments for similar conditions.
On January 6, 2026, Derek Archila from Wells Fargo set a new price target for ALMS at $39. At the time, the stock was trading at approximately $16.97, suggesting a potential upside of about 70.16%. This optimistic outlook coincides with Alumis's announcement of its Phase 3 ONWARD clinical program results, which are crucial for the company's future growth.
The stock for ALMS is currently priced at $15.90, showing a significant increase of 91.33% with a change of $7.59. Today, the stock has fluctuated between a low of $15.47 and a high of $22.30, marking its highest price over the past year. The lowest price for the year was $2.76, indicating substantial volatility and investor interest.
Alumis has a market capitalization of approximately $1.66 billion, reflecting its position in the biopharmaceutical industry. The trading volume for the day is 53.93 million shares on the NASDAQ exchange, highlighting the heightened activity and interest in the stock, especially with the upcoming clinical data announcement.
The announcement of the Phase 3 ONWARD clinical program results is a significant milestone for Alumis. The company will host a conference call and webcast at 8:00 a.m. ET to discuss the results, which could further influence the stock's performance and investor sentiment.
